Your Tech Transfer Questions Answered: How To Successfully Onshore A Mid-Phase Project

By Rich Richieri, Chief Operations Officer, Avid Bioservices

Offshoring biologic manufacturing was once a strategic choice to save money. However, in response to several factors, many drug sponsors are now opting to onshore their operations to domestic CDMOs. This shift has been perpetuated by geopolitical tensions, supply chain instability, and regulatory incentives, but ultimately, for most U.S. sponsors, it is a way to mitigate uncertainty. An ideal sponsor and CDMO relationship affords stability and reliability, and in the current geopolitical environment, a domestic CDMO is better suited to provide both.

While opting to onshore operations from an international to a domestic CDMO in the mid-phase of development is achievable, it entails unique challenges that can delay project timelines. But, with a knowledgeable CDMO that has previously navigated mid-phase tech transfer, you can alleviate these obstacles to steer your products toward commercial success. Download the full article to explore the reasons behind the onshoring push and what you can do to mitigate risks during tech transfer.